Cancer startup PMV Pharma gains impressive $74M B round

This latest round builds on its 2014 $30 million Series A funding.

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this round), and its Series A lead investor OrbiMed.

The company said it will use its new cash boost for work on its p53-targeted small molecule drugs in cancer, building on the $30 million it got back in December 2014.

PMV says its target is the most commonly mutated protein in human cancers, with more than half of all tumors containing mutant p53, something that can help them evade death.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The biotech is designing its pipeline around the promise that could see it restore p53 to its normal function, therefore removing its ability to escape and selectively killing the mutant cancer cells, all, crucially, without affecting normal tissues, something that causes adverse events.

The biotech was founded by p53 thought leader Arnold Levine as well as the world-renowned virologist Thomas Shenk.

“PMV Pharmaceutical's world-class founders, scientific advisers, and leadership team, together with its transformative chemistry and biology platform position PMV Pharma to be a leader in next-generation cancer therapies to improve patients’ lives,” said Steve Winick of Topspin, who also joins PMV’s board.

“This financing provides PMV Pharma with the resources to broadly expand our pipeline and to bring p53 therapies to the clinic,” added David Mack, president and CEO of PMV Pharmaceuticals.

“We are excited to have Topspin join us in our pursuit of developing meaningful new medicines for large segments of the cancer population. The enthusiasm and confidence from our new and existing investors underscore the important advances we have made.”

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.